⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
businesswire.com
VNDA
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
prnewswire.com
VNDA
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
prnewswire.com
ABBV
ALTO
NRXP
VNDA
Form 8-K
sec.gov
VNDA
Crafting Announces General Availability of Crafting for Agents and $5.5M Seed Round to Build Infrastructure for AI-Driven Engineering
globenewswire.com
VNDA
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ANAB
VNDA
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
prnewswire.com
VNDA